Company:Dharmacon, Inc.

Dharmacon, Inc.

Type	Subsidiary
Industry	Biotech
Founded	1995 by Stephen Scaringe
Headquarters	Lafayette, CO, USA
Products	CRISPR, RNAi, siRNA, miRNA, shRNA, cDNA, ORFs, Transfection Reagents
Number of employees	150 (2014)
Website	http://www.Dharmacon.com

Dharmacon Inc., now known as Dharmacon, a Horizon Discovery Group company, was founded in 1995 by Stephen Scaringe as Dharmacon Research to develop and commercialize a new technology for RNA oligonucleotide synthesis. The original Dharmacon focus and vision was to develop 2'-ACE RNA technology as the standard for RNA synthesis and to advance RNA oligo-dependent applications and technologies. When RNA interference (RNAi) emerged in the late 1990s, Dharmacon was poised to provide RNAi-related products to the multitude of academic and industry researchers. Dharmacon has become an important resource for those investigating the mechanisms of siRNA (small interfering RNA)-induced gene knockdown and applying the specificity and potency of RNAi to human biotherapeutics. Dharmacon's expertise in bioinformatics, RNA biology, and synthesis chemistry has allowed it to develop a complete line of products for the RNAi researcher.

In November 2002, Dharmacon Research, Inc. officially changed its name to Dharmacon, Inc., to reflect the increasing capabilities and future growth potential of the company, as it had advanced beyond research and development and into whole solutions for RNA oligo-dependent applications and technologies. In March 2004, Dharmacon became a wholly owned subsidiary of Fisher Scientific International, Inc. In November 2006, Fisher Scientific International, Inc. merged with Thermo Electron Corporation to become Thermo Fisher Scientific.

In October 2012 the websites for the companies formerly known as Dharmacon, Open Biosystems, Fermentas, Finnzymes, and ABgene were merged, creating the new Thermo Scientific Life Sciences Research eCommerce site.

In April 2013, Thermo Fisher Scientific reached an agreement to buy Life Technologies Corporation. The acquisition of Life Technologies Corporation received conditional approval from the European Commission in November 2013. The conditional requirement was the divestment of Thermo Fisher Scientific's cell culture (sera and media), magnetic beads and Dharmacon gene modulation businesses for antitrust reasons.

In early January 2014, GE Healthcare reached an agreement with Thermo Fisher Scientific to acquire the cell culture, magnetic bead and Dharmacon gene modulation businesses for 1.05 billion USD. The acquisition of Dharmacon is viewed as complementary to GE Healthcare's drug discovery research technologies.

In the fall of 2014, GE Healthcare announced it had reached a licensing agreement with the Broad Institute of MIT and Harvard granting access to CRISPR-Cas9 intellectual property. Under the agreement, GE Healthcare is able to incorporate the patented technologies, and develop and launch additional complementary gene editing reagents. Then, in October 2014, GE Healthcare Dharmacon launched its first CRISPR-Cas9 genome engineering products under the “Edit-R” brand. In July 2015, GE Healthcare Dharmacon launched synthetic crRNA and lentiviral sgRNA pre-designed with a functionally validated algorithm against entire human, mouse and rat genomes.

In July 2017, UK firm Horizon Discovery reached an agreement to acquire Dharmacon from GE Healthcare for a total consideration of $85 million. The acquisition is expected to complement Horizon's portfolio of gene editing products and engineered cell lines.

Products

Gene Editing

• CRISPR-Cas9
  • CRISPR Guide RNA
  • CAS9 Nuclease
  • CRISPR Controls
  • CRISPR Screening Libraries

RNA Interference

• siRNA
• shRNA
• microRNA
• Screening Libraries
• Controls
• Ancillary Reagents

cDNAs and ORFs

• Mammalian cDNAs
• Mammalian ORFs
• Non-Mammalian cDNAs and ORFs
• cDNA and ORF Libraries